These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 29905005

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer.
    Choi SY, Xue H, Wu R, Fazli L, Lin D, Collins CC, Gleave ME, Gout PW, Wang Y.
    Clin Cancer Res; 2016 Jun 01; 22(11):2721-33. PubMed ID: 26755530
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells.
    Braadland PR, Ramberg H, Grytli HH, Urbanucci A, Nielsen HK, Guldvik IJ, Engedal A, Ketola K, Wang W, Svindland A, Mills IG, Bjartell A, Taskén KA.
    Mol Cancer Res; 2019 Nov 01; 17(11):2154-2168. PubMed ID: 31395667
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. WLS-Wnt signaling promotes neuroendocrine prostate cancer.
    Bland T, Wang J, Yin L, Pu T, Li J, Gao J, Lin TP, Gao AC, Wu BJ.
    iScience; 2021 Jan 22; 24(1):101970. PubMed ID: 33437943
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer.
    Hsu EC, Shen M, Aslan M, Liu S, Kumar M, Garcia-Marques F, Nguyen HM, Nolley R, Pitteri SJ, Corey E, Brooks JD, Stoyanova T.
    Sci Rep; 2021 Jun 25; 11(1):13305. PubMed ID: 34172788
    [Abstract] [Full Text] [Related]

  • 14. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.
    Lin D, Dong X, Wang K, Wyatt AW, Crea F, Xue H, Wang Y, Wu R, Bell RH, Haegert A, Brahmbhatt S, Hurtado-Coll A, Gout PW, Fazli L, Gleave ME, Collins CC, Wang Y.
    Oncotarget; 2015 Jan 30; 6(3):1806-20. PubMed ID: 25544761
    [Abstract] [Full Text] [Related]

  • 15. Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells.
    Chen R, Li Y, Buttyan R, Dong X.
    Oncotarget; 2017 Oct 17; 8(49):84863-84876. PubMed ID: 29156689
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
    Li Y, Xie N, Chen R, Lee AR, Lovnicki J, Morrison EA, Fazli L, Zhang Q, Musselman CA, Wang Y, Huang J, Gleave ME, Collins C, Dong X.
    Eur Urol; 2019 Aug 17; 76(2):157-166. PubMed ID: 30910347
    [Abstract] [Full Text] [Related]

  • 19. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
    Lee AR, Gan Y, Tang Y, Dong X.
    EBioMedicine; 2018 Sep 17; 35():167-177. PubMed ID: 30100395
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.